H3B-6527

H3B-6527 is an orally active, highly selective and covalent FGFR4 inhibitor with an IC50 of IC50s of 320 nM, 1290 nM and 1060 nM respectively. H3B-6527 has potent anti-cancer activity[1].

Product Specifications

CAS Number

[1702259-66-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

FGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/H3B-6527.html

Purity

98.0

Solubility

DMSO : 2.5 mg/mL (ultrasonic)

Smiles

C=CC(NC1=CC(N2CCN(CC)CC2)=CC=C1NC3=NC=NC(N(C(NC4=C(Cl)C(OC)=CC(OC)=C4Cl)=O)C)=C3)=O

Molecular Formula

C29H34Cl2N8O4

Molecular Weight

629.54

Precautions

H302, H315, H319, H335

References & Citations

[1]Joshi JJ, et al. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven HepatocellularCarcinoma. Cancer Res. 2017 Dec 15;77 (24) :6999-7013.